Skip to search formSkip to main contentSkip to account menu

dehydroxymethylepoxyquinomicin

Known as: DHMEQ cpd 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesCyclohexanones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Pleiotropic Potential of Dehydroxymethylepoxyquinomicin for NF-κB Suppression via Reactive Oxygen Species and Unfolded Protein Response
Dehydroxymethylepoxyquinomicin (DHMEQ) is a low-m.w. compound that strongly inhibits NF-κB. Previous reports showed that DHMEQ… 
2011
2011
Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2.
Dehydroxymethylepoxyquinomicin (DHMEQ, 1a) is a specific and potent inhibitor of NF-κB, and it is now being developed as an anti… 
2007
2007
Targeting NF-kappaB and induction of apoptosis by novel NF-kappaB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells.
A new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt… 
2006
2006
Control of Allograft Rejection by Applying a Novel Nuclear Factor-&kgr;B Inhibitor, Dehydroxymethylepoxyquinomicin
Background. Nuclear factor (NF)-&kgr;B plays a crucial role in lymphocyte activation, proliferation, and survival. We examined… 
Review
2006
Review
2006
Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Adult T-cell leukemia/lymphoma (ATL), a fatal T-cell leukemia/lymphoma resistant to chemotherapy, is caused by human T-cell… 
Highly Cited
2005
Highly Cited
2005
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear… 
2005
2005
Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.
2005
2005
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Nuclear factor-kappaB (NF-kappaB) is constitutively activated in multiple myeloma cells. Several proteasome inhibitors have been… 
2005
2005
Prevention of Cancer Cachexia by a Novel Nuclear Factor κB Inhibitor in Prostate Cancer
Purpose: To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the… 
2005
2005
Prevention of cancer cachexia by a novel nuclear factor {kappa}B inhibitor in prostate cancer.
PURPOSE To investigate the association between serum interleukin-6 (IL-6) and cachexia in patients with prostate cancer and the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)